| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 88 | 2025 | 664 | 13.190 |
Why?
|
| Diabetes Mellitus | 90 | 2023 | 452 | 11.240 |
Why?
|
| Hypoglycemia | 22 | 2025 | 46 | 6.940 |
Why?
|
| Hypoglycemic Agents | 41 | 2025 | 250 | 6.120 |
Why?
|
| Medication Adherence | 25 | 2020 | 235 | 5.330 |
Why?
|
| Blood Glucose Self-Monitoring | 16 | 2021 | 37 | 3.680 |
Why?
|
| Humans | 232 | 2025 | 17314 | 3.680 |
Why?
|
| Middle Aged | 162 | 2025 | 7836 | 3.660 |
Why?
|
| Male | 179 | 2025 | 9804 | 3.640 |
Why?
|
| Blood Glucose | 42 | 2025 | 314 | 3.620 |
Why?
|
| Aged | 134 | 2025 | 6084 | 3.340 |
Why?
|
| Female | 183 | 2025 | 12396 | 3.320 |
Why?
|
| Glycated Hemoglobin A | 36 | 2021 | 184 | 3.290 |
Why?
|
| California | 76 | 2020 | 2311 | 2.870 |
Why?
|
| Diabetes Mellitus, Type 1 | 16 | 2022 | 118 | 2.860 |
Why?
|
| Physician-Patient Relations | 11 | 2020 | 163 | 2.850 |
Why?
|
| Health Literacy | 10 | 2021 | 38 | 2.850 |
Why?
|
| Residence Characteristics | 9 | 2017 | 253 | 2.330 |
Why?
|
| Adult | 102 | 2023 | 7500 | 2.270 |
Why?
|
| Communication Barriers | 8 | 2017 | 29 | 2.130 |
Why?
|
| Ethnic Groups | 24 | 2016 | 451 | 1.970 |
Why?
|
| Aging | 12 | 2019 | 160 | 1.920 |
Why?
|
| Socioeconomic Factors | 31 | 2017 | 605 | 1.840 |
Why?
|
| Cardiovascular Diseases | 19 | 2021 | 532 | 1.800 |
Why?
|
| Diabetes Complications | 17 | 2020 | 105 | 1.770 |
Why?
|
| Food Supply | 5 | 2018 | 41 | 1.760 |
Why?
|
| Insulin | 20 | 2025 | 188 | 1.650 |
Why?
|
| Electronic Health Records | 10 | 2020 | 704 | 1.630 |
Why?
|
| Cohort Studies | 41 | 2025 | 2514 | 1.610 |
Why?
|
| Body Mass Index | 17 | 2017 | 937 | 1.540 |
Why?
|
| Hospitalization | 9 | 2024 | 804 | 1.520 |
Why?
|
| Managed Care Programs | 22 | 2017 | 300 | 1.490 |
Why?
|
| Dyslipidemias | 3 | 2019 | 56 | 1.470 |
Why?
|
| Insulin Resistance | 23 | 2016 | 128 | 1.450 |
Why?
|
| Pharmaceutical Services | 6 | 2019 | 34 | 1.450 |
Why?
|
| Delivery of Health Care, Integrated | 11 | 2017 | 535 | 1.430 |
Why?
|
| Risk Assessment | 18 | 2023 | 1076 | 1.400 |
Why?
|
| Hispanic Americans | 20 | 2017 | 375 | 1.400 |
Why?
|
| Risk Factors | 59 | 2023 | 3258 | 1.390 |
Why?
|
| Population Surveillance | 5 | 2018 | 252 | 1.380 |
Why?
|
| Dementia | 9 | 2025 | 121 | 1.360 |
Why?
|
| Insurance, Health | 9 | 2017 | 170 | 1.210 |
Why?
|
| European Continental Ancestry Group | 20 | 2017 | 476 | 1.200 |
Why?
|
| Retrospective Studies | 24 | 2025 | 2415 | 1.190 |
Why?
|
| Aged, 80 and over | 31 | 2025 | 1925 | 1.190 |
Why?
|
| Depression | 13 | 2017 | 486 | 1.190 |
Why?
|
| United States | 49 | 2025 | 3866 | 1.170 |
Why?
|
| Health Status Disparities | 5 | 2017 | 149 | 1.170 |
Why?
|
| Postal Service | 7 | 2020 | 72 | 1.150 |
Why?
|
| Communication | 6 | 2020 | 178 | 1.110 |
Why?
|
| Patient Compliance | 9 | 2011 | 277 | 1.090 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2019 | 165 | 1.080 |
Why?
|
| Health Expenditures | 3 | 2017 | 72 | 1.070 |
Why?
|
| Culturally Competent Care | 2 | 2017 | 11 | 1.070 |
Why?
|
| Continental Population Groups | 16 | 2016 | 286 | 1.050 |
Why?
|
| Cross-Sectional Studies | 35 | 2017 | 1280 | 1.040 |
Why?
|
| Commerce | 2 | 2017 | 36 | 1.020 |
Why?
|
| Health Behavior | 13 | 2015 | 346 | 1.020 |
Why?
|
| Quality of Life | 6 | 2017 | 499 | 0.990 |
Why?
|
| Follow-Up Studies | 25 | 2018 | 1151 | 0.980 |
Why?
|
| Obesity | 14 | 2017 | 814 | 0.980 |
Why?
|
| Professional-Patient Relations | 5 | 2014 | 48 | 0.970 |
Why?
|
| Prescription Drugs | 3 | 2017 | 30 | 0.960 |
Why?
|
| Glycemic Index | 5 | 2010 | 19 | 0.950 |
Why?
|
| Language | 7 | 2016 | 49 | 0.950 |
Why?
|
| Diabetic Angiopathies | 11 | 2015 | 31 | 0.930 |
Why?
|
| Electronic Prescribing | 3 | 2015 | 5 | 0.910 |
Why?
|
| Coronary Disease | 2 | 2016 | 146 | 0.900 |
Why?
|
| Patient Acceptance of Health Care | 6 | 2018 | 381 | 0.890 |
Why?
|
| Self Care | 9 | 2014 | 144 | 0.880 |
Why?
|
| Atherosclerosis | 4 | 2021 | 52 | 0.870 |
Why?
|
| Trust | 3 | 2014 | 32 | 0.870 |
Why?
|
| Registries | 20 | 2020 | 460 | 0.860 |
Why?
|
| Emergency Service, Hospital | 5 | 2018 | 384 | 0.850 |
Why?
|
| Drug Utilization | 5 | 2016 | 121 | 0.840 |
Why?
|
| Prospective Studies | 18 | 2020 | 1226 | 0.830 |
Why?
|
| Glucose | 1 | 2023 | 31 | 0.830 |
Why?
|
| Cost Sharing | 3 | 2017 | 28 | 0.830 |
Why?
|
| Tool Use Behavior | 1 | 2023 | 2 | 0.810 |
Why?
|
| Arteriosclerosis | 11 | 2005 | 16 | 0.810 |
Why?
|
| Health Maintenance Organizations | 8 | 2010 | 407 | 0.780 |
Why?
|
| Cholesterol, LDL | 8 | 2016 | 112 | 0.770 |
Why?
|
| Educational Status | 12 | 2014 | 177 | 0.770 |
Why?
|
| Antidepressive Agents | 2 | 2014 | 142 | 0.770 |
Why?
|
| African Americans | 13 | 2017 | 439 | 0.760 |
Why?
|
| Treatment Outcome | 11 | 2021 | 1160 | 0.750 |
Why?
|
| Biosensing Techniques | 1 | 2021 | 4 | 0.710 |
Why?
|
| Incidence | 20 | 2017 | 1266 | 0.710 |
Why?
|
| Deductibles and Coinsurance | 3 | 2017 | 31 | 0.700 |
Why?
|
| Diabetic Neuropathies | 2 | 2016 | 10 | 0.690 |
Why?
|
| Diabetic Nephropathies | 4 | 2015 | 25 | 0.690 |
Why?
|
| Patient Education as Topic | 3 | 2020 | 193 | 0.680 |
Why?
|
| Thiazolidinediones | 5 | 2010 | 50 | 0.670 |
Why?
|
| Housing | 3 | 2017 | 37 | 0.670 |
Why?
|
| Economic Recession | 2 | 2017 | 4 | 0.660 |
Why?
|
| Data Accuracy | 2 | 2023 | 24 | 0.650 |
Why?
|
| Crime | 3 | 2016 | 22 | 0.650 |
Why?
|
| Health Records, Personal | 3 | 2015 | 10 | 0.640 |
Why?
|
| Safety | 2 | 2016 | 43 | 0.630 |
Why?
|
| Self Report | 6 | 2020 | 257 | 0.610 |
Why?
|
| Insurance, Pharmaceutical Services | 3 | 2014 | 23 | 0.610 |
Why?
|
| Insulin Detemir | 1 | 2018 | 1 | 0.590 |
Why?
|
| Insulin, Isophane | 1 | 2018 | 2 | 0.590 |
Why?
|
| Insulin Glargine | 1 | 2018 | 8 | 0.590 |
Why?
|
| Stress, Psychological | 2 | 2016 | 134 | 0.580 |
Why?
|
| Appointments and Schedules | 2 | 2011 | 25 | 0.570 |
Why?
|
| Internet | 3 | 2017 | 212 | 0.570 |
Why?
|
| Kidney Failure, Chronic | 6 | 2011 | 151 | 0.560 |
Why?
|
| Environment | 2 | 2017 | 50 | 0.550 |
Why?
|
| African Continental Ancestry Group | 9 | 2016 | 144 | 0.540 |
Why?
|
| Health Status | 4 | 2017 | 293 | 0.540 |
Why?
|
| Emergency Medical Services | 1 | 2017 | 48 | 0.540 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2017 | 302 | 0.540 |
Why?
|
| Patient Handoff | 1 | 2017 | 2 | 0.540 |
Why?
|
| Social Support | 3 | 2014 | 207 | 0.520 |
Why?
|
| Health Services Accessibility | 9 | 2017 | 271 | 0.510 |
Why?
|
| Cardiovascular Agents | 1 | 2016 | 22 | 0.510 |
Why?
|
| Primary Health Care | 5 | 2017 | 726 | 0.510 |
Why?
|
| Cities | 1 | 2016 | 30 | 0.510 |
Why?
|
| Geographic Information Systems | 1 | 2016 | 15 | 0.500 |
Why?
|
| Young Adult | 17 | 2020 | 2465 | 0.500 |
Why?
|
| Smoking | 12 | 2021 | 429 | 0.500 |
Why?
|
| Algorithms | 3 | 2025 | 223 | 0.490 |
Why?
|
| Time Factors | 12 | 2021 | 1039 | 0.480 |
Why?
|
| Hypertriglyceridemia | 1 | 2015 | 12 | 0.480 |
Why?
|
| Databases, Pharmaceutical | 1 | 2015 | 6 | 0.470 |
Why?
|
| Age Factors | 8 | 2017 | 878 | 0.470 |
Why?
|
| Life Style | 3 | 2014 | 316 | 0.470 |
Why?
|
| Poverty Areas | 1 | 2015 | 21 | 0.470 |
Why?
|
| Longitudinal Studies | 14 | 2020 | 674 | 0.460 |
Why?
|
| Coronary Artery Disease | 1 | 2015 | 112 | 0.450 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2015 | 184 | 0.450 |
Why?
|
| Statistics as Topic | 1 | 2015 | 56 | 0.450 |
Why?
|
| Health Surveys | 10 | 2015 | 245 | 0.440 |
Why?
|
| Quality Improvement | 3 | 2025 | 188 | 0.440 |
Why?
|
| Glucose Intolerance | 10 | 2013 | 43 | 0.430 |
Why?
|
| Fasting | 6 | 2016 | 46 | 0.430 |
Why?
|
| Financing, Personal | 3 | 2017 | 18 | 0.420 |
Why?
|
| Antihypertensive Agents | 7 | 2015 | 154 | 0.420 |
Why?
|
| Decision Making | 2 | 2014 | 171 | 0.420 |
Why?
|
| Outcome Assessment (Health Care) | 6 | 2012 | 215 | 0.420 |
Why?
|
| Glomerular Filtration Rate | 2 | 2015 | 153 | 0.420 |
Why?
|
| Patient Access to Records | 1 | 2013 | 12 | 0.410 |
Why?
|
| Amputation | 2 | 2011 | 11 | 0.400 |
Why?
|
| Cognition | 4 | 2022 | 81 | 0.390 |
Why?
|
| Comorbidity | 15 | 2018 | 560 | 0.380 |
Why?
|
| Sulfonylurea Compounds | 3 | 2025 | 25 | 0.370 |
Why?
|
| Temperature | 2 | 2017 | 19 | 0.360 |
Why?
|
| Adolescent | 13 | 2017 | 3538 | 0.360 |
Why?
|
| Heart Failure | 4 | 2015 | 401 | 0.360 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2011 | 12 | 0.350 |
Why?
|
| Triglycerides | 2 | 2011 | 83 | 0.350 |
Why?
|
| Multivariate Analysis | 9 | 2015 | 535 | 0.350 |
Why?
|
| Proportional Hazards Models | 9 | 2017 | 701 | 0.350 |
Why?
|
| Outcome and Process Assessment (Health Care) | 6 | 2010 | 97 | 0.340 |
Why?
|
| Body Constitution | 5 | 2005 | 39 | 0.340 |
Why?
|
| Myocardial Ischemia | 3 | 2004 | 23 | 0.340 |
Why?
|
| Healthcare Disparities | 5 | 2016 | 202 | 0.330 |
Why?
|
| Dental Care for Chronically Ill | 1 | 2010 | 1 | 0.330 |
Why?
|
| Insurance, Dental | 1 | 2010 | 4 | 0.330 |
Why?
|
| Chronic Disease | 3 | 2009 | 397 | 0.330 |
Why?
|
| Referral and Consultation | 1 | 2011 | 157 | 0.320 |
Why?
|
| Office Visits | 1 | 2010 | 73 | 0.320 |
Why?
|
| Anemia | 1 | 2010 | 32 | 0.320 |
Why?
|
| Patient-Centered Care | 1 | 2011 | 186 | 0.310 |
Why?
|
| Quality of Health Care | 9 | 2011 | 259 | 0.310 |
Why?
|
| Medicare | 3 | 2015 | 192 | 0.310 |
Why?
|
| Genetic Variation | 2 | 2015 | 77 | 0.310 |
Why?
|
| Asian Americans | 6 | 2012 | 163 | 0.300 |
Why?
|
| Health Care Surveys | 8 | 2013 | 211 | 0.300 |
Why?
|
| Hypolipidemic Agents | 5 | 2015 | 38 | 0.300 |
Why?
|
| Myocardial Infarction | 4 | 2015 | 224 | 0.290 |
Why?
|
| Electronic Mail | 2 | 2019 | 51 | 0.280 |
Why?
|
| Alcohol Drinking | 5 | 2008 | 356 | 0.280 |
Why?
|
| Physicians | 2 | 2020 | 117 | 0.270 |
Why?
|
| Premature Birth | 2 | 2020 | 132 | 0.270 |
Why?
|
| Pregnancy Outcome | 2 | 2014 | 158 | 0.270 |
Why?
|
| Cost of Illness | 2 | 2007 | 92 | 0.260 |
Why?
|
| Asian Continental Ancestry Group | 4 | 2016 | 87 | 0.250 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2006 | 37 | 0.250 |
Why?
|
| Body Size | 1 | 2006 | 31 | 0.250 |
Why?
|
| Carotid Artery Diseases | 2 | 2003 | 11 | 0.250 |
Why?
|
| Risk | 4 | 2013 | 496 | 0.240 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2025 | 8 | 0.240 |
Why?
|
| Surveys and Questionnaires | 9 | 2018 | 1282 | 0.240 |
Why?
|
| Deprescriptions | 1 | 2025 | 10 | 0.230 |
Why?
|
| Prevalence | 9 | 2020 | 840 | 0.230 |
Why?
|
| Health Personnel | 4 | 2020 | 126 | 0.230 |
Why?
|
| Confidence Intervals | 3 | 2021 | 231 | 0.230 |
Why?
|
| Survival Rate | 7 | 2015 | 252 | 0.230 |
Why?
|
| Poisson Distribution | 3 | 2015 | 85 | 0.230 |
Why?
|
| Medicaid | 2 | 2017 | 189 | 0.230 |
Why?
|
| Cost-Benefit Analysis | 3 | 2015 | 226 | 0.220 |
Why?
|
| Renal Dialysis | 2 | 2004 | 57 | 0.220 |
Why?
|
| Insurance Coverage | 3 | 2017 | 104 | 0.220 |
Why?
|
| Linguistics | 2 | 2021 | 4 | 0.220 |
Why?
|
| Sex Factors | 7 | 2017 | 603 | 0.220 |
Why?
|
| Linear Models | 6 | 2013 | 206 | 0.220 |
Why?
|
| Quality Indicators, Health Care | 4 | 2014 | 125 | 0.220 |
Why?
|
| Data Collection | 4 | 2014 | 238 | 0.220 |
Why?
|
| Cognitive Dysfunction | 2 | 2022 | 53 | 0.210 |
Why?
|
| Perception | 3 | 2016 | 56 | 0.210 |
Why?
|
| Tuberculosis | 1 | 2004 | 24 | 0.210 |
Why?
|
| Polypharmacy | 2 | 2016 | 13 | 0.210 |
Why?
|
| Pharmacies | 2 | 2015 | 9 | 0.210 |
Why?
|
| Oceanic Ancestry Group | 3 | 2012 | 33 | 0.210 |
Why?
|
| Hypertension | 8 | 2015 | 469 | 0.210 |
Why?
|
| Disease Management | 3 | 2015 | 111 | 0.200 |
Why?
|
| Epidemiology | 1 | 2003 | 6 | 0.200 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2014 | 367 | 0.200 |
Why?
|
| Patient Satisfaction | 4 | 2011 | 191 | 0.200 |
Why?
|
| Natural Language Processing | 2 | 2020 | 60 | 0.200 |
Why?
|
| Prejudice | 3 | 2011 | 22 | 0.200 |
Why?
|
| Glucose Tolerance Test | 7 | 2004 | 107 | 0.200 |
Why?
|
| Life Tables | 1 | 2012 | 7 | 0.190 |
Why?
|
| Hyperlipidemias | 4 | 2011 | 44 | 0.190 |
Why?
|
| Research Design | 5 | 2023 | 336 | 0.190 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 437 | 0.180 |
Why?
|
| Preventive Health Services | 1 | 2003 | 147 | 0.180 |
Why?
|
| Abortion, Spontaneous | 1 | 2012 | 49 | 0.180 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 143 | 0.180 |
Why?
|
| Numbers Needed To Treat | 1 | 2021 | 2 | 0.180 |
Why?
|
| Selection Bias | 1 | 2021 | 16 | 0.180 |
Why?
|
| Health Services Research | 3 | 2013 | 202 | 0.180 |
Why?
|
| Motor Activity | 2 | 2013 | 208 | 0.180 |
Why?
|
| Diabetic Retinopathy | 2 | 2014 | 17 | 0.180 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2011 | 74 | 0.170 |
Why?
|
| Income | 5 | 2014 | 86 | 0.170 |
Why?
|
| Propensity Score | 1 | 2021 | 76 | 0.170 |
Why?
|
| Cerebrovascular Disorders | 2 | 2013 | 31 | 0.170 |
Why?
|
| Health Services Needs and Demand | 1 | 2021 | 87 | 0.170 |
Why?
|
| Pharmacy | 1 | 2020 | 12 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2025 | 312 | 0.170 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2020 | 6 | 0.170 |
Why?
|
| Cause of Death | 4 | 2015 | 176 | 0.160 |
Why?
|
| Philippines | 3 | 2015 | 25 | 0.160 |
Why?
|
| Withholding Treatment | 1 | 2019 | 26 | 0.160 |
Why?
|
| Genomic Imprinting | 1 | 1999 | 2 | 0.160 |
Why?
|
| Sleep | 1 | 2020 | 57 | 0.160 |
Why?
|
| Child Development | 1 | 2020 | 53 | 0.160 |
Why?
|
| Poverty | 3 | 2015 | 168 | 0.150 |
Why?
|
| Models, Statistical | 3 | 2017 | 170 | 0.150 |
Why?
|
| Insurance Claim Review | 4 | 2015 | 49 | 0.150 |
Why?
|
| Reindeer | 2 | 1996 | 2 | 0.150 |
Why?
|
| Feeding Behavior | 2 | 2018 | 163 | 0.150 |
Why?
|
| San Francisco | 2 | 2016 | 59 | 0.140 |
Why?
|
| Caregivers | 1 | 2019 | 128 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2015 | 372 | 0.140 |
Why?
|
| Logistic Models | 6 | 2014 | 879 | 0.140 |
Why?
|
| Dietary Fats | 2 | 2001 | 89 | 0.140 |
Why?
|
| Social Class | 2 | 2011 | 116 | 0.140 |
Why?
|
| Albuminuria | 3 | 2015 | 35 | 0.140 |
Why?
|
| Food | 2 | 2018 | 36 | 0.140 |
Why?
|
| Population Dynamics | 1 | 2017 | 6 | 0.140 |
Why?
|
| Reproducibility of Results | 6 | 2012 | 357 | 0.130 |
Why?
|
| Forecasting | 2 | 2015 | 68 | 0.130 |
Why?
|
| Medically Uninsured | 1 | 2017 | 41 | 0.130 |
Why?
|
| Health Benefit Plans, Employee | 1 | 2017 | 16 | 0.130 |
Why?
|
| Vulnerable Populations | 1 | 2017 | 34 | 0.130 |
Why?
|
| Police | 1 | 2016 | 1 | 0.130 |
Why?
|
| Substance-Related Disorders | 1 | 2011 | 425 | 0.130 |
Why?
|
| Longevity | 3 | 2022 | 12 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 114 | 0.130 |
Why?
|
| Needs Assessment | 1 | 2017 | 65 | 0.130 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2020 | 151 | 0.130 |
Why?
|
| Influenza Vaccines | 1 | 2020 | 292 | 0.130 |
Why?
|
| Influenza, Human | 1 | 2020 | 282 | 0.130 |
Why?
|
| Self Efficacy | 2 | 2014 | 68 | 0.130 |
Why?
|
| Pregnancy | 4 | 2020 | 1463 | 0.130 |
Why?
|
| Appetite | 1 | 1996 | 1 | 0.120 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 1996 | 1 | 0.120 |
Why?
|
| Nematode Infections | 1 | 1996 | 1 | 0.120 |
Why?
|
| Disease Progression | 4 | 2016 | 259 | 0.120 |
Why?
|
| Analysis of Variance | 2 | 2015 | 139 | 0.120 |
Why?
|
| Medical Order Entry Systems | 1 | 2015 | 10 | 0.120 |
Why?
|
| Cholesterol, HDL | 1 | 2015 | 69 | 0.120 |
Why?
|
| Nutrition Surveys | 2 | 2018 | 56 | 0.120 |
Why?
|
| Fast Foods | 1 | 2015 | 12 | 0.120 |
Why?
|
| Mutation Rate | 1 | 2015 | 3 | 0.120 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 24 | 0.120 |
Why?
|
| Exome | 1 | 2015 | 21 | 0.120 |
Why?
|
| Blood Chemical Analysis | 1 | 2014 | 4 | 0.120 |
Why?
|
| Safety-net Providers | 1 | 2015 | 55 | 0.110 |
Why?
|
| Spatial Analysis | 1 | 2014 | 11 | 0.110 |
Why?
|
| Observational Studies as Topic | 1 | 2015 | 47 | 0.110 |
Why?
|
| Remission Induction | 1 | 2014 | 26 | 0.110 |
Why?
|
| Weight Gain | 1 | 2016 | 156 | 0.110 |
Why?
|
| Drug Prescriptions | 2 | 2013 | 146 | 0.110 |
Why?
|
| Metabolic Syndrome | 2 | 2005 | 65 | 0.110 |
Why?
|
| Health Resources | 1 | 2014 | 34 | 0.110 |
Why?
|
| Regression Analysis | 4 | 2012 | 270 | 0.110 |
Why?
|
| Health Care Costs | 2 | 2006 | 207 | 0.110 |
Why?
|
| Case-Control Studies | 5 | 2013 | 1098 | 0.110 |
Why?
|
| Metformin | 2 | 2020 | 50 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2016 | 363 | 0.110 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2014 | 22 | 0.110 |
Why?
|
| Terminology as Topic | 1 | 2013 | 15 | 0.100 |
Why?
|
| Urinary Incontinence | 1 | 2013 | 27 | 0.100 |
Why?
|
| Prediabetic State | 2 | 2013 | 52 | 0.100 |
Why?
|
| Apolipoproteins | 1 | 2013 | 2 | 0.100 |
Why?
|
| Lipoproteins | 1 | 2013 | 13 | 0.100 |
Why?
|
| Reference Values | 3 | 2008 | 87 | 0.100 |
Why?
|
| Antiviral Agents | 1 | 2014 | 99 | 0.100 |
Why?
|
| Diptera | 1 | 1992 | 1 | 0.100 |
Why?
|
| Humidity | 1 | 1992 | 3 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 3 | 2014 | 81 | 0.100 |
Why?
|
| Psychometrics | 1 | 2013 | 119 | 0.100 |
Why?
|
| Bariatric Surgery | 1 | 2014 | 129 | 0.100 |
Why?
|
| Musculoskeletal Pain | 1 | 2012 | 24 | 0.090 |
Why?
|
| Odds Ratio | 2 | 2013 | 640 | 0.090 |
Why?
|
| Medical Records | 3 | 2007 | 91 | 0.090 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2003 | 100 | 0.090 |
Why?
|
| Death Certificates | 1 | 2011 | 17 | 0.090 |
Why?
|
| Discrimination (Psychology) | 1 | 2011 | 1 | 0.090 |
Why?
|
| Interpersonal Relations | 1 | 2011 | 41 | 0.090 |
Why?
|
| Prognosis | 5 | 2016 | 603 | 0.090 |
Why?
|
| Sex Distribution | 4 | 2012 | 180 | 0.090 |
Why?
|
| Ambulatory Care Information Systems | 1 | 2011 | 3 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2025 | 310 | 0.090 |
Why?
|
| Age Distribution | 4 | 2012 | 239 | 0.090 |
Why?
|
| Databases, Factual | 3 | 2013 | 304 | 0.090 |
Why?
|
| Blood Pressure | 4 | 2016 | 275 | 0.090 |
Why?
|
| Prescription Fees | 1 | 2010 | 4 | 0.090 |
Why?
|
| Cost Control | 1 | 2010 | 13 | 0.090 |
Why?
|
| Patients | 1 | 2010 | 29 | 0.080 |
Why?
|
| Guideline Adherence | 2 | 2009 | 149 | 0.080 |
Why?
|
| Comprehension | 1 | 2010 | 18 | 0.080 |
Why?
|
| Hawaii | 2 | 2020 | 58 | 0.080 |
Why?
|
| Accidental Falls | 1 | 2009 | 46 | 0.080 |
Why?
|
| Fractures, Bone | 1 | 2010 | 92 | 0.080 |
Why?
|
| Insulin-Secreting Cells | 1 | 2009 | 18 | 0.080 |
Why?
|
| Primary Prevention | 1 | 2010 | 62 | 0.080 |
Why?
|
| Patient Selection | 2 | 2008 | 176 | 0.080 |
Why?
|
| Drug Therapy | 1 | 2009 | 16 | 0.080 |
Why?
|
| Predictive Value of Tests | 5 | 2012 | 342 | 0.080 |
Why?
|
| Body Weight | 2 | 2003 | 203 | 0.070 |
Why?
|
| Depressive Disorder, Major | 1 | 2009 | 100 | 0.070 |
Why?
|
| Exercise | 5 | 2016 | 515 | 0.070 |
Why?
|
| Infant | 2 | 2020 | 1161 | 0.070 |
Why?
|
| International Classification of Diseases | 3 | 2015 | 86 | 0.070 |
Why?
|
| Treatment Refusal | 1 | 2008 | 30 | 0.070 |
Why?
|
| Social Problems | 1 | 2007 | 7 | 0.070 |
Why?
|
| Drug Costs | 1 | 2007 | 32 | 0.070 |
Why?
|
| Torticollis | 1 | 2007 | 3 | 0.070 |
Why?
|
| Self Disclosure | 1 | 2007 | 19 | 0.070 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2007 | 19 | 0.070 |
Why?
|
| Health Status Indicators | 1 | 2007 | 59 | 0.070 |
Why?
|
| Walking | 1 | 2008 | 89 | 0.070 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2006 | 53 | 0.070 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2006 | 84 | 0.070 |
Why?
|
| Translational Medical Research | 3 | 2012 | 33 | 0.070 |
Why?
|
| Sex Characteristics | 3 | 2004 | 66 | 0.070 |
Why?
|
| Seasons | 1 | 2017 | 113 | 0.060 |
Why?
|
| Monte Carlo Method | 1 | 2006 | 12 | 0.060 |
Why?
|
| Markov Chains | 1 | 2006 | 22 | 0.060 |
Why?
|
| State Medicine | 1 | 2006 | 5 | 0.060 |
Why?
|
| United Kingdom | 1 | 2006 | 25 | 0.060 |
Why?
|
| Stroke | 2 | 2015 | 309 | 0.060 |
Why?
|
| Reagent Strips | 1 | 2006 | 1 | 0.060 |
Why?
|
| Mass Screening | 2 | 2014 | 672 | 0.060 |
Why?
|
| Education, Medical, Continuing | 1 | 2006 | 31 | 0.060 |
Why?
|
| PPAR gamma | 1 | 2005 | 9 | 0.060 |
Why?
|
| Minority Groups | 2 | 2011 | 104 | 0.060 |
Why?
|
| Age of Onset | 2 | 2020 | 70 | 0.060 |
Why?
|
| Child | 2 | 2020 | 2403 | 0.060 |
Why?
|
| Abdomen | 1 | 2005 | 20 | 0.060 |
Why?
|
| Models, Genetic | 1 | 2005 | 23 | 0.060 |
Why?
|
| Pedigree | 1 | 2005 | 63 | 0.060 |
Why?
|
| Demography | 3 | 2013 | 93 | 0.060 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2025 | 61 | 0.060 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2004 | 8 | 0.060 |
Why?
|
| Self-Management | 1 | 2024 | 24 | 0.050 |
Why?
|
| Hypercholesterolemia | 1 | 2004 | 25 | 0.050 |
Why?
|
| Animals | 2 | 1996 | 280 | 0.050 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2003 | 5 | 0.050 |
Why?
|
| Lipoproteins, LDL | 1 | 2003 | 12 | 0.050 |
Why?
|
| Genetics, Population | 1 | 2003 | 8 | 0.050 |
Why?
|
| Progestins | 1 | 2003 | 25 | 0.050 |
Why?
|
| Health Education | 1 | 2003 | 82 | 0.050 |
Why?
|
| Comparative Effectiveness Research | 1 | 2023 | 62 | 0.050 |
Why?
|
| Activities of Daily Living | 2 | 2013 | 81 | 0.050 |
Why?
|
| Estrogens | 1 | 2003 | 60 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2013 | 202 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2014 | 86 | 0.050 |
Why?
|
| Databases, Bibliographic | 1 | 2012 | 6 | 0.050 |
Why?
|
| Public Health | 1 | 2003 | 83 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2004 | 225 | 0.050 |
Why?
|
| Fibrinogen | 1 | 2001 | 12 | 0.050 |
Why?
|
| Gestational Age | 1 | 2012 | 112 | 0.050 |
Why?
|
| Alcoholics Anonymous | 1 | 2011 | 14 | 0.050 |
Why?
|
| Adipose Tissue | 1 | 2001 | 65 | 0.050 |
Why?
|
| Texas | 2 | 2003 | 41 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2001 | 58 | 0.040 |
Why?
|
| Evidence-Based Medicine | 2 | 2014 | 169 | 0.040 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2001 | 70 | 0.040 |
Why?
|
| Colorado | 2 | 2003 | 164 | 0.040 |
Why?
|
| Models, Theoretical | 2 | 2016 | 67 | 0.040 |
Why?
|
| Writing | 1 | 2020 | 11 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2001 | 71 | 0.040 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 390 | 0.040 |
Why?
|
| Machine Learning | 1 | 2020 | 53 | 0.040 |
Why?
|
| Attitude of Health Personnel | 2 | 2013 | 197 | 0.040 |
Why?
|
| Executive Function | 1 | 2019 | 23 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2004 | 1380 | 0.040 |
Why?
|
| Proxy | 1 | 2019 | 3 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 2019 | 30 | 0.040 |
Why?
|
| Vaccines, Inactivated | 1 | 2020 | 72 | 0.040 |
Why?
|
| Nuclear Family | 1 | 1999 | 7 | 0.040 |
Why?
|
| Fathers | 1 | 1999 | 9 | 0.040 |
Why?
|
| Confidentiality | 1 | 2019 | 25 | 0.040 |
Why?
|
| Focus Groups | 1 | 2019 | 143 | 0.040 |
Why?
|
| Mothers | 1 | 1999 | 103 | 0.040 |
Why?
|
| Geography | 1 | 2018 | 39 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2019 | 260 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 65 | 0.040 |
Why?
|
| Biomarkers | 2 | 2013 | 307 | 0.030 |
Why?
|
| Acitretin | 1 | 1997 | 1 | 0.030 |
Why?
|
| Psoriasis | 1 | 1997 | 9 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2020 | 805 | 0.030 |
Why?
|
| Software | 1 | 1997 | 19 | 0.030 |
Why?
|
| Professional Competence | 1 | 2016 | 11 | 0.030 |
Why?
|
| Computer Simulation | 1 | 1997 | 80 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2016 | 1 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2016 | 4 | 0.030 |
Why?
|
| Introns | 1 | 2016 | 9 | 0.030 |
Why?
|
| Islets of Langerhans | 1 | 2016 | 11 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2016 | 39 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2016 | 19 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2016 | 38 | 0.030 |
Why?
|
| Mortality | 1 | 1997 | 116 | 0.030 |
Why?
|
| Unemployment | 1 | 2016 | 12 | 0.030 |
Why?
|
| Abomasum | 1 | 1996 | 1 | 0.030 |
Why?
|
| Antinematodal Agents | 1 | 1996 | 1 | 0.030 |
Why?
|
| Cestoda | 1 | 1996 | 1 | 0.030 |
Why?
|
| Coccidia | 1 | 1996 | 1 | 0.030 |
Why?
|
| Ivermectin | 1 | 1996 | 1 | 0.030 |
Why?
|
| Nematoda | 1 | 1996 | 1 | 0.030 |
Why?
|
| Parasite Egg Count | 1 | 1996 | 1 | 0.030 |
Why?
|
| Animals, Domestic | 1 | 1996 | 4 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 120 | 0.030 |
Why?
|
| Diet | 3 | 2006 | 355 | 0.030 |
Why?
|
| Urban Population | 1 | 2016 | 109 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 59 | 0.030 |
Why?
|
| Feces | 1 | 1996 | 85 | 0.030 |
Why?
|
| Epidemiological Monitoring | 1 | 2015 | 24 | 0.030 |
Why?
|
| Information Storage and Retrieval | 1 | 2015 | 15 | 0.030 |
Why?
|
| Vitamin A Deficiency | 1 | 1995 | 3 | 0.030 |
Why?
|
| Glucose-6-Phosphatase | 1 | 2015 | 2 | 0.030 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2015 | 3 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 248 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 33 | 0.030 |
Why?
|
| Models, Biological | 2 | 2006 | 28 | 0.030 |
Why?
|
| Blood Pressure Determination | 1 | 2015 | 52 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2015 | 54 | 0.030 |
Why?
|
| Mathematical Concepts | 1 | 2014 | 3 | 0.030 |
Why?
|
| Self Administration | 1 | 2014 | 9 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1995 | 63 | 0.030 |
Why?
|
| Maternal Age | 1 | 2014 | 74 | 0.030 |
Why?
|
| Diabetic Foot | 1 | 2013 | 3 | 0.030 |
Why?
|
| Indians, North American | 1 | 2013 | 48 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2014 | 104 | 0.030 |
Why?
|
| Inflammation | 2 | 2005 | 63 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 123 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 146 | 0.030 |
Why?
|
| Larva | 1 | 1992 | 1 | 0.020 |
Why?
|
| Oviposition | 1 | 1992 | 1 | 0.020 |
Why?
|
| Ovum | 1 | 1992 | 2 | 0.020 |
Why?
|
| Sickness Impact Profile | 1 | 2012 | 25 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 24 | 0.020 |
Why?
|
| New Jersey | 1 | 2012 | 4 | 0.020 |
Why?
|
| Indiana | 1 | 2012 | 3 | 0.020 |
Why?
|
| Employment | 1 | 2012 | 44 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2011 | 51 | 0.020 |
Why?
|
| Far East | 1 | 2011 | 6 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2010 | 13 | 0.020 |
Why?
|
| HIV Infections | 1 | 1997 | 712 | 0.020 |
Why?
|
| Mobility Limitation | 1 | 2010 | 16 | 0.020 |
Why?
|
| Choice Behavior | 1 | 2010 | 45 | 0.020 |
Why?
|
| Diet, Diabetic | 1 | 2010 | 7 | 0.020 |
Why?
|
| Pain | 1 | 2010 | 75 | 0.020 |
Why?
|
| Attitude to Health | 1 | 2011 | 147 | 0.020 |
Why?
|
| Energy Metabolism | 2 | 2001 | 48 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 99 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2009 | 72 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2009 | 306 | 0.020 |
Why?
|
| Medical Audit | 1 | 2008 | 32 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 71 | 0.020 |
Why?
|
| Drug Utilization Review | 1 | 2007 | 23 | 0.020 |
Why?
|
| Anxiety | 1 | 2009 | 154 | 0.020 |
Why?
|
| Feedback | 1 | 2006 | 20 | 0.020 |
Why?
|
| Information Systems | 1 | 2006 | 14 | 0.020 |
Why?
|
| Reminder Systems | 1 | 2006 | 74 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2005 | 28 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2005 | 18 | 0.010 |
Why?
|
| Haplotypes | 1 | 2005 | 34 | 0.010 |
Why?
|
| Alleles | 1 | 2005 | 80 | 0.010 |
Why?
|
| Genotype | 1 | 2005 | 223 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 2003 | 22 | 0.010 |
Why?
|
| Biology | 1 | 2003 | 1 | 0.010 |
Why?
|
| Sociology | 1 | 2003 | 3 | 0.010 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2003 | 9 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2003 | 33 | 0.010 |
Why?
|
| Anthropometry | 1 | 2003 | 60 | 0.010 |
Why?
|
| Culture | 1 | 2003 | 30 | 0.010 |
Why?
|
| Energy Intake | 1 | 2003 | 98 | 0.010 |
Why?
|
| Genomics | 1 | 2003 | 56 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 107 | 0.010 |
Why?
|
| Factor Analysis, Statistical | 1 | 2002 | 36 | 0.010 |
Why?
|
| Creatinine | 1 | 2002 | 66 | 0.010 |
Why?
|
| Postmenopause | 1 | 2003 | 248 | 0.010 |
Why?
|
| Carotid Arteries | 1 | 2001 | 8 | 0.010 |
Why?
|
| Infection | 1 | 2001 | 17 | 0.010 |
Why?
|
| Body Composition | 1 | 2001 | 91 | 0.010 |
Why?
|
| Leisure Activities | 1 | 2001 | 34 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1997 | 211 | 0.010 |
Why?
|
| New York City | 1 | 1995 | 24 | 0.010 |
Why?
|
| Vitamin A | 1 | 1995 | 14 | 0.010 |
Why?
|
| Nutritional Status | 1 | 1995 | 32 | 0.010 |
Why?
|
| Eating | 1 | 1995 | 34 | 0.010 |
Why?
|